GlaxoSmithKline’s Pharmaceuticals Segment in 2Q17
GlaxoSmithKline’s (GSK) Pharmaceuticals segment includes HIV (human immunodeficiency virus) products, immuno-inflammation products, respiratory products, and established products. The segment reported a 3.0% rise in revenues at constant exchange rates and a 9.0% positive impact of foreign exchange in 2Q17.
Interested in GSK? Don't miss the next report.
Receive e-mail alerts for new research on GSK
The above chart shows revenues of key pharmaceutical products. The Pharmaceuticals segment reported revenues of 4.4 billion pounds in 2Q17, driven by the increase in sales of HIV products Triumeq and Tivicay and other products such as Relvar/Breo Ellipta and Nucala, partially offset by the impact of divestitures.
GlaxoSmithKline’s HIV products are marketed by ViiV Healthcare, a company with GlaxoSmithKline as a major shareholder; Pfizer (PFE); Shionogi; and others. HIV products reported a 17.0% rise in revenues at constant exchange rates to 1.1 billion pounds in 2Q17 compared to 2Q16.
Global pharmaceuticals include other therapeutic areas such as respiratory products, immuno-inflammation products, and established products. Total revenues from global pharmaceuticals were 3.2 billion pounds in 2Q17.
At constant exchange rates, immuno-inflammation products reported revenues of 93.0 million pounds in 2Q17, a 9.0% rise compared to 2Q16. Respiratory products reported revenues of 1.8 billion pounds in 2Q17, a 4.0% rise compared to 2Q16. However, at constant exchange rates, the established pharmaceuticals franchise reported a 7.0% fall in revenues of 1.4 billion pounds in 2Q17.
The Vanguard FTSE Developed Markets ETF (VEA) has 0.50% of its total assets in GlaxoSmithKline. VEA also holds 0.50% in Sanofi (SNY), 0.10% in Teva Pharmaceutical Industries (TEVA), and 0.40% in Novo Nordisk (NVO).